APA (7th ed.) Citation

Sokolenko, A., Preobrazhenskaya, E., Marchetti, C., Piermattei, A., Zagrebin, F., Kuligina, E., . . . Imyanitov, E. (2024). Origin of Residual Tumor Masses in BRCA1/2-Driven Ovarian Carcinomas Treated by Neoadjuvant Chemotherapy: Selection of Preexisting BRCA1/2-Proficient Tumor Cells but Not the Gain of Second ORF-Restoring Mutation. Pathobiology, 91(2), 108. https://doi.org/10.1159/000533591

Chicago Style (17th ed.) Citation

Sokolenko, Anna, et al. "Origin of Residual Tumor Masses in BRCA1/2-Driven Ovarian Carcinomas Treated by Neoadjuvant Chemotherapy: Selection of Preexisting BRCA1/2-Proficient Tumor Cells but Not the Gain of Second ORF-Restoring Mutation." Pathobiology 91, no. 2 (2024): 108. https://doi.org/10.1159/000533591.

MLA (9th ed.) Citation

Sokolenko, Anna, et al. "Origin of Residual Tumor Masses in BRCA1/2-Driven Ovarian Carcinomas Treated by Neoadjuvant Chemotherapy: Selection of Preexisting BRCA1/2-Proficient Tumor Cells but Not the Gain of Second ORF-Restoring Mutation." Pathobiology, vol. 91, no. 2, 2024, p. 108, https://doi.org/10.1159/000533591.